Skip Navigation

A Phase III, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer

Brief Summary

Type:
Pancreatic

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT03941093

Study #:
STUDY00145047

Start Date:
May 19, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03941093

View Complete Trial Details & Eligibility at ClinicalTrials.gov